Exploring novel immunotherapy biomarker candidates induced by cancer deformation
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303433 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Se Min Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Life Science and Biotechnology Department (LSBT), Underwood Division (UD), Underwood International College, Yonsei University, Sinchon, Seoul, Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Elsa U Pardee Foundation, MCC Patient Gift Fund.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) demands urgent attention for the development of effective treatment strategies due to its aggressiveness and limited therapeutic options [1]. This research is primarily focused on identifying new biomarkers vital for immunotherapy, with the aim of developing tailored treatments specifically for TNBC, such as those targeting the PD-1/PD-L1 pathway. To achieve this, the study places a strong emphasis on investigating Ig genes, a characteristic of immune checkpoint inhibitors, particularly genes expressing Ig-like domains with altered expression levels induced by "cancer deformation," a condition associated with cancer malignancy. Human cells can express approximately 800 Ig family genes, yet only a few Ig genes, including PD-1 and PD-L1, have been developed into immunotherapy drugs thus far. Therefore, we investigated the Ig genes that were either upregulated or downregulated by the artificial metastatic environment in TNBC cell line. As a result, we confirmed the upregulation of approximately 13 Ig genes and validated them using qPCR. In summary, our study proposes an approach for identifying new biomarkers applicable to future immunotherapies aimed at addressing challenging cases of TNBC where conventional treatments fall short.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Life Science and Biotechnology Department (LSBT), Underwood Division (UD), Underwood International College, Yonsei University, Sinchon, Seoul, Korea.
- Department of Biomedical Informatics & Medical Education, University of Washington, Seattle, Washington, United States of America.
- Digital Health Care Research Center, Gumi Electronics and Information Technology Research Institute (GERI), Gumidaero, Gumi, Gyeongbuk, South Korea.
- Department of Bioengineering, University of Washington, Seattle, Washington, United States of America.
- Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, United States of America.
- Division of Advanced Materials Engineering, Kongju National University, Chungnam, South Korea.
ORCID-Profile: Se Min Kim, Sekyu Choi, Jung Hyun Lee
Förderung
- The Elsa U Pardee Foundation
- MCC Patient Gift Fund
Zitieren
APA
Kim, S. M., Park, N., Park, H. B., Lee, J., Chun, C., Kim, K. H., Choi, J. S., Kim, H. J., Choi, S., & Lee, J. H. (2024). Exploring novel immunotherapy biomarker candidates induced by cancer deformation. PLOS ONE. https://doi.org/10.1371/journal.pone.0303433
Vancouver
Kim SM, Park N, Park HB, Lee J, Chun C, Kim KH, et al. Exploring novel immunotherapy biomarker candidates induced by cancer deformation. PLOS ONE. 2024. doi:10.1371/journal.pone.0303433
BibTeX
@article{Kim2024,
author = {Kim, Se Min and Park, Namu and Park, Hye Bin and Lee, JuKyung and Chun, Changho and Kim, Kyung Hoon and Choi, Jong Seob and Kim, Hyung Jin and Choi, Sekyu and Lee, Jung Hyun},
title = {Exploring novel immunotherapy biomarker candidates induced by cancer deformation},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303433}
}
EUVIMED